DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology partner, Crucell, have signed a PER.C6 license agreement with Biotecnol SA, a Portuguese biotechnology company and its U.S.-based subsidiary Biotecnol, Inc. This license agreement allows Biotecnol to use the PER.C6 human cell line for preclinical and Phase I development of its proprietary antibody products, which are composed of Tribodies and Compact Antibodies. Under the terms of the agreement, Biotecnol...